Danish industrial biotech startup EvodiaBio has raised €6 million in a funding round led by US-based RA Capital, with continued backing from EIFO and participation from new international investors Francis Family Funds and Wild Radicals. The company develops fermentation-driven technology that enables the efficient, scalable, and low-carbon production of natural aroma molecules—initially transforming beer production by reducing reliance on climate-vulnerable hops, with broader applications across beverages and flavors. With documented commercial traction among global breweries and industrial-scale production already in place, EvodiaBio will use the new capital to accelerate expansion across Europe, the US, and Canada, while preparing entry into Asia and extending its platform into adjacent aroma and flavor segments.
EvodiaBio has developed a proprietary technology platform that enables the industrial production of volatile aroma molecules in a significantly more efficient and sustainable way than traditional methods. While the company’s first commercial traction has come from the beer industry—where its technology reduces dependence on hops increasingly threatened by climate change—the platform is designed for broader use across beverages, flavors, and aroma applications.
Having moved from research to industrial production in just a few years, EvodiaBio says it has now eliminated its major technological and commercial risks and is entering a new growth phase focused on international expansion.
“This investment makes us a fully scalable company. I am proud of our team – in just three and a half years we have gone from research project to industrial production with all necessary approvals and a profitable product. This is rarely seen in the biotech industry. The investment gives us the opportunity to accelerate growth globally and realize our ambition to become a Danish unicorn within industrial biotech,” said Camilla Kloss Fenneberg, CEO of EvodiaBio.
The new capital will be used to strengthen EvodiaBio’s position in existing markets across Europe, the US, and Canada, while preparing entry into Asia as the next step in its expansion strategy. Since launching its commercial product earlier this year, the company has completed more than 70 commercial brews and is running over 10 projects with top-40 breweries worldwide, underlining growing market adoption.
According to Jarne Elleholm, Chairman of the Board of Directors of EvodiaBio, the timing of RA Capital’s entry reflects how far the company has progressed:
“RA Capital’s entry into EvodiaBio at this time underlines the company’s strong position. It confirms that we have removed the most significant risks within technology, production and commercialization. We have proven that the technology works, that customers are interested in the product and that the business model has been profitable from the start. Now we are ready to accelerate growth.”
Elleholm added that the company’s trajectory is unusual even by biotech standards:
“What EvodiaBio has achieved in record time is exceptional in our industry. Going from the laboratory to a full production platform, global partnerships and market interest in such a short time shows that Denmark has the potential to become a biosolutions beacon. The new capital gives us the opportunity to accelerate even further and show how far industrial biotech can take Denmark.”
From the investor side, RA Capital highlighted both the technical and commercial maturity of EvodiaBio’s platform.
“EvodiaBio has developed a technology platform that convincingly solves one of the most complex problems in the flavor and beverage industry: how to efficiently and sustainably produce natural flavors on an industrial scale. The team has executed with a speed and quality rarely seen in biotech, and we see tremendous global potential,” said Kyle Teamey, Managing Partner at RA Capital.
Teamey also pointed to the company’s readiness for rapid international scaling:
“It is exceptional that a biotech company has both its own production, validated technology, strong commercial demand and established distribution partners already at this point. With Symrise and Lallemand as channels, EvodiaBio has a unique opportunity for rapid market access. We look forward to supporting the company in scaling internationally and expanding the technology into new segments.”
Looking ahead, EvodiaBio plans to apply its fermentation technology beyond beer into other beverages, wine, and the wider flavor industry, with Asia identified as a key growth market.
“This investment puts us in a strong position to accelerate our growth and expand our technology to new markets, especially in Asia. We have achieved strong commercial validation, but we are still early in our growth journey. Our goal is to become a global leader in industrial biotech, and we see a huge opportunity to revolutionize multiple industries with our sustainable and efficient solutions,” said Fenneberg.
The round is EvodiaBio’s third funding raise in three years, bringing total capital raised to approximately €20 million (DKK 150 million). The company is backed by a high-profile board that includes Flemming Besenbacher (former Chairman of Carlsberg), Andreas Fibig (former CEO of IFF), and Anne Cabotin (former SVP at Symrise), reinforcing its ambition to build a globally leading industrial biotech platform from Denmark.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/evodiabio-raises-e6-million/
